BioMarin Pharmaceutical Says European Commission Has Granted Conditional Marketing Authorization To ROCTAVIAN Gene Therapy
Maintains Orphan Drug Designation (ODD) in the EU Providing 10-years of Market Exclusivity
Significant Benefit Over Existing Therapies for Patients with Severe Hemophilia A in EU Based on EMA Determination of
